The cell-extrinsic PD-L1, high expressed PD-L1 on the surface of cancer or immune cells, is pathogenic primarily by inhibiting CD8+ cytotoxic T cells and contributes to the development of immune checkpoint blockade in treating NSCLC. This evidence concerns the gene CD8A and non-small cell lung carcinoma.